FOOTHILL RANCH, Calif.,
Nov. 17, 2021 /PRNewswire/
-- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental
lasers, encourages stockholders to vote TODAY "FOR" the
amendment to the BIOLASE, Inc. Certificate of Incorporation to
effect a reverse stock split (without reducing the authorized
number of shares of common stock) (the "amendment" or the "reverse
stock split"). The special meeting of BIOLASE stockholders is
scheduled to be held at 10:00 a.m. Pacific
Time on Friday, November 19, 2021.
With the special meeting only days away, BIOLASE
stockholders are urged to vote now online or by
telephone to ensure their shares are represented at the
special meeting. It is critical that stockholders vote, no
matter how many shares they own. The reverse stock split
will not affect stockholders' percentage ownership of BIOLASE.
Our Board Strongly Recommends That Stockholders Approve the
Amendment. Approving the amendment will:
- Help ensure continued listing of our common stock on The Nasdaq
- Attract institutional investors and promote greater liquidity
for our stockholders,
- Enable us to offer equity compensation to employees and other
service providers (and, thus, conserve cash), and
- Provide that shares of common stock are authorized and
available for future uses.
Leading Proxy Advisory Firms Institutional Shareholder
Services and Glass, Lewis & Co., LLC Have Each Recommended
That Stockholders Vote "FOR" the Reverse Stock
Stockholders can vote by following the easy instructions on the
proxy card. If you have already submitted a proxy, you may
change your vote prior to the special meeting by voting again using
the same materials. Only your latest dated vote counts.
If you hold at Robinhood, look for an email from Proxydocs.com, and
for all other stockholders, check for an email from
Your Vote Is Important, No Matter How Many or
How Few Shares You Own.
BIOLASE stockholders who need assistance in voting their shares
may contact BIOLASE's proxy solicitor, DF King, by emailing
BIOL@dfking.com or calling (800) 347-4750.
An AST Company
48 Wall Street, 22nd Floor
New York, NY 10005
Call Toll-Free: (800) 347-4750
Banks and Brokers Call: (212) 269-5550
BIOLASE is a medical device company that develops, manufactures,
markets, and sells laser systems in dentistry and medicine.
BIOLASE's products advance the practice of dentistry and medicine
for patients and healthcare professionals. BIOLASE's proprietary
laser products incorporate approximately 271 patented and 40
patent-pending technologies designed to provide biologically and
clinically superior performance with less pain and faster recovery
times. BIOLASE's innovative products provide cutting-edge
technology at competitive prices to deliver superior results for
dentists and patients. BIOLASE's principal products are
revolutionary dental laser systems that perform a broad range of
dental procedures, including cosmetic and complex surgical
applications. BIOLASE has sold over 41,200 laser systems to date in
over 80 countries around the world. Laser products under
development address BIOLASE's core dental market and other adjacent
medical and consumer applications.
For updates and information on Waterlase iPlus®, Waterlase
Express™, and laser dentistry, find BIOLASE online at
www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at
www.twitter.com/biolaseinc, Instagram at
www.instagram.com/waterlase_laserdentistry, and LinkedIn at
BIOLASE®, Waterlase® and Waterlase iPlus® are registered
trademarks of BIOLASE, Inc.
Cautionary Statement Regarding Forward-Looking
This communication contains forward-looking statements, as that
term is defined in the Private Litigation Reform Act of 1995, that
involve significant risks and uncertainties, including statements
regarding the anticipated effects of stockholder approval of the
reverse stock split to be voted on at the special meeting.
Forward-looking statements can be identified through the use of
words such as "may," "might," "will," "intend," "should," "could,"
"can," "would," "continue," "expect," "believe," "anticipate,"
"estimate," "predict," "potential," "plan," "seek," and similar
expressions. Readers are cautioned not to place undue reliance on
these forward-looking statements, which reflect our current
expectations and speak only as of the date of this communication.
These factors include, among others, those risks and uncertainties
that are described in the definitive proxy statement we filed with
the Securities and Exchange Commission (the "SEC") in connection
with the special meeting and in the "Risk Factors" section of our
most recent annual report on Form 10-K and our most
recent quarterly report on Form 10-Q filed with the SEC.
Except as required by law, we do not undertake any responsibility
to revise or update any forward-looking statements.
1 Third-party statements should not be viewed as
indicating the support of such third party for the views expressed
in this press release.
View original content to download
SOURCE BIOLASE, Inc.